Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19

South Valley University

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Covid19

Treatments: Drug: intranasal ivermectin spray

Study type: Interventional

Funder types: Other

Identifiers

NCT04716569

SVU MED CIT0 23 4 21 1 120

Details and patient eligibility

About

Ivermectin showed a strong viricidal effect upon covid19 virus in vitro as proved by many authors according to many studies , covid virus stay in postnasal space for 4 days before starting general manifestation, so ivermectin mucoadhesive nanosuspension sprayed inside the nose and post nasal space may help in early management of covid19 and may play a great rule in prophylaxis as well

Full description

150 patient with early covid is devided into two groups first group will receive regular protocol of drugs second group will receive ivermectin nasal spray in addition to regular protocl of drugs

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• early covid19 pateints

Exclusion criteria

• children and pregnant women

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

150 participants in 2 patient groups

intranasal Ivermectin group

Experimental group

Description:

Ivermectin group Patients who will receive intranasal ivermectin

Treatment:

Drug: intranasal ivermectin spray

Control group

Other group

Description:

patients who will receive regular protocol drugs

Treatment:

Drug: intranasal ivermectin spray